Currently, there are 59.52M common shares owned by the public and among those 55.85M shares have been available to trade.
The company’s stock has a 5-day price change of 31.50% and -37.96% over the past three months. APTO shares are trading -90.20% year to date (YTD), with the 12-month market performance down to -88.99% lower. It has a 12-month low price of $0.13 and touched a high of $2.68 over the same period. APTO has an average intraday trading volume of 6.04 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 28.06%, -16.26%, and -65.28% respectively.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Institutional ownership of Aptose Biosciences Inc (NASDAQ: APTO) shares accounts for 5.43% of the company’s 59.52M shares outstanding.
It has a market capitalization of $14.81M and a beta (3y monthly) value of 0.83. The earnings-per-share (ttm) stands at -$3.05. Price movements for the stock have been influenced by the stock’s volatility, which stands at 24.00% over the week and 15.00% over the month.
Looking at the support for the APTO, a number of firms have released research notes about the stock. Cantor Fitzgerald stated their Overweight rating for the stock in a research note on October 19, 2020, with the firm’s price target at $10. Alliance Global Partners coverage for the Aptose Biosciences Inc (APTO) stock in a research note released on September 22, 2020 offered a Buy rating with a price target of $12. Maxim Group was of a view on February 20, 2020 that the stock is Buy, while H.C. Wainwright gave the stock Buy rating on February 06, 2020, issuing a price target of $6- $9. Piper Sandler on their part issued Overweight rating on January 09, 2020.
